Cite
APA Citation
Amorim, S., Stathis, A., Gleeson, M., Iyengar, S., Magarotto, V., Leleu, X., Morschhauser, F., Karlin, L., Broussais, F., Rezai, K., Herait, P., Kahatt, C., Lokiec, F., Salles, G., Facon, T., Palumbo, A., Cunningham, D., Zucca, E., & Thieblemont, C. (2016). bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet, 3(4), e196–e204. http://access.bl.uk/ark:/81055/vdc_100054580845.0x00000c